Milestone Scientific Appoints Pain Management Industry Veteran Dr. Didier Demesmin to its Board of Directors
September 12 2023 - 11:00AM
Milestone Scientific Inc. (NYSE: MLSS), a leading
developer of computerized drug delivery instruments that provide
painless and precise injections, today announced the appointment of
Dr. Didier Demesmin, MD, MBA, to the Board of Directors.
Dr. Demesmin is an interventional pain medicine
physician who is double board-certified in both anesthesiology and
pain medicine. He is the founder of University Pain and Spine
center, a well-respected interventional pain management and spine
surgery clinic that operates 7 offices across New Jersey and New
York. He is also the founder of STEMMEE Surgery Center, an
ambulatory surgery center providing state of the art surgical and
interventional procedures. Dr. Demesmin is also affiliated with
some of the most well-respected hospitals in Central New Jersey,
such as Robert Wood Johnson University Hospital, JFK Medical
Center, Somerset Medical Center, and Saint Peter’s University
Hospital, where he is the director of pain medicine. He is also an
assistant clinical professor at Rutgers Robert Wood Johnson Medical
School. Dr. Demesmin earned his medical degree from Robert Wood
Johnson Medical School and completed his anesthesia residency
training at SUNY Downstate Medical Center and his interventional
pain fellowship program at Columbia University, College of
Physicians and Surgeons-St. Luke’s Roosevelt Medical Center in New
York. He holds an MBA from Northwestern-Kellogg School of
Management.
Neal Goldman, Chairman of the Board of Directors
at Milestone Scientific, stated, "We are pleased to announce the
appointment of Dr. Demesmin to the Board of Directors at a key
inflection point for the Company, as we advance the commercial
rollout of our epidural instrument to the global marketplace. Dr.
Demesmin has become a major advocate of the technology, following a
successful evaluation and adoption of the system at his medical
practice. Importantly, Dr. Demesmin brings almost twenty years of
experience in pain management and business, which should be an
invaluable asset as we seek to expand market adoption of our
CompuFlo Epidural System among pain management clinics and
anesthesiologists, given his first hand experience. Based on the
growing recognition of our technology, we remain confident that the
CompuFlo Epidural system will, in time, become the standard of care
in epidural analgesia.”
Dr. Didier Demesmin stated, “I am honored to
join Milestone at this exciting time in the Company’s evolution.
Having evaluated Milestone’s CompuFlo System within my clinic, I
have had an inside look into the market potential of Milestone’s
painless and precise computerized injection technology platform to
transform drug delivery in pain management. The system has proven
to be a valuable tool in helping navigate the challenging
anatomical regions in the lumbar and thoracic region and cervical
thoracic junction, which offers a number of advantages in terms of
safety and efficacy. I look forward to helping convert the growing
enthusiasm among medical practitioners into broad global commercial
adoption.”
About Milestone Scientific
Inc.Milestone Scientific Inc. (MLSS), a technology focused
medical research and development company that patents, designs and
develops innovative injection technologies and instruments for
medical, dental and cosmetic applications. Milestone Scientific’s
computer-controlled systems are designed to make injections
precise, efficient and increase the overall patient comfort and
safety. Their proprietary DPS Dynamic Pressure Sensing Technology®
instruments is the platform to advance the development of
next-generation devices, regulating flow rate and monitoring
pressure from the tip of the needle, through platform extensions of
subcutaneous drug delivery, including local anesthetic. To learn
more, view the MLSS brand video or visit
milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking
statements regarding the timing and financial impact of Milestone's
ability to implement its business plan, expected revenues, timing
of regulatory approvals and future success. These statements
involve a number of risks and uncertainties and are based on
assumptions involving judgments with respect to future economic,
competitive and market conditions, future business decisions and
regulatory developments, all of which are difficult or impossible
to predict accurately and many of which are beyond Milestone's
control. Some of the important factors that could cause actual
results to differ materially from those indicated by the
forward-looking statements are general economic conditions, failure
to achieve expected revenue growth, changes in our operating
expenses, adverse patent rulings, FDA or legal developments,
competitive pressures, changes in customer and market requirements
and standards, and the risk factors detailed from time to time in
Milestone's periodic filings with the Securities and Exchange
Commission, including without limitation, Milestone's Annual Report
for the year ended December 31, 2022. The forward-looking
statements in this press release are based upon management's
reasonable belief as of the date hereof. Milestone undertakes no
obligation to revise or update publicly any forward-looking
statements for any reason.
Contact:Crescendo
Communications, LLCEmail: mlss@crescendo-ir.comTel:
212-671-1020
Milestone Scientific (AMEX:MLSS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Milestone Scientific (AMEX:MLSS)
Historical Stock Chart
From Sep 2023 to Sep 2024